Science

Dec 29, 2024, 10:10

Neoadjuvant atezolizumab plus chemotherapy for resectable NSCLC

Journal for ImmunoTherapy of Cancer posted on X about recent paper by Brian S. Henick et al., titled “Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings“.

Authors: Brian S. Henick, Peter D. Koch, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Stephanie Izard, Yohanna Georgis, Samyukta Mallick, Robert F. Garofano, Cheryl V. Wong, Anjali Saqi, Jessica Grindheim, Katja Schulze, Joshua R. Sonett, Naiyer A. Rizvi, Benjamin Izar, Alison M. Taylor, Catherine A. Shu

“New JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.”

Alison M. Taylor Anjali Saqi Benjamin Izar Brian S Henick cancer Catherine A. Shu Cheryl V. Wong Codruta Chiuzan Jessica Grindheim Joshua R. Sonett Journal for ImmunoTherapy of Cancer Justin F. Gainor Katja Schulze Mark M. Awad Naiyer A. Rizvi NSCLC OncoDaily Oncology Peter D. Koch Robert F. Garofano Samyukta Mallick Stephanie Izard Yohanna Georgis

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025